Tyme Technologies (TYME.Q) announced today that the United States Patent and Trademark Office has granted the Company additional patent claims related to the Company’s metabolomic technology platform.
“This delivery technology is another example of our innovative spirit at Tyme. Even though this approach is still in its early stages, if proven, it has the potential to be a broadly leveraged platform technology.” said Richie Cunningham, CEO of Tyme.
Tyme is an emerging biotechnology company focused on the development of cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of tumor types while maintaining low toxicity profiles. Unlike conventional targeted therapies that attempt to regulate specific mutations within cancer, Tyme’s CMBTs™ are designed to take advantage of a cancer cell’s innate metabolic weakness. In doing so, the Company’s CMBTs™ are able to compromise a cancer cell’s defenses resulting in cell death through oxidative stress and exposure to the body’s natural immune system.
So how do CMBTs™ work? Tyme’s CMBTs utilize tyrosine isomer racemetyrosine, which can be fused with a second therapeutic agent. For context, racemetyrosine is like tyrosine’s cool lab-developed brother, described as the modified and dysfunctional version of tyrosine, a naturally occurring amino acid. Upon https://e4njohordzs.exactdn.com/wp-content/uploads/2021/10/tnw8sVO3j-2.pngistration, racemetyrosine is specifically taken up by cancer cells, preventing mucin-1 (MUC1) protein synthesis in cancer cells. Keep in mind, MUC1 is part of the protective layer on the outside of cancer cells, and plays a key role in defending cancer cells from the immune system. By preventing protein synthesis, racemetyrosine is able to create a absence of MUC1, thereby compromising a cancer cell’s defense. In doing so, the cancer cell is more vulnerable to being recognized and attacked by the body’s immune system.
With this in mind, Tyme’s CMBTs™ are predicated on the metabolic phenomenon in which cancer cells consume higher quantities of non-essential amino acids, including tyrosine, from their surrounding environment to support their growth. Under the guise of tyrosine, racemetyrosine is also consumed by cancer cells, similar to how the Greeks infiltrated Troy with their Trojan Horse. So what would happen if you used this technology to deliver toxic therapies directly to cancer cells? Well, you’d have a pretty kickass platform with increased safety and efficacy compared to traditional targeted therapies.
“This technology could provide Tyme an opportunity to expand its current cancer-metabolism based approach with a drug delivery platform that’s aimed to deliver toxic therapies in a targeted manner that could offer improved safety and efficacy for a range of anticancer drugs.” said Steve Hoffman, Tyme’s Chief Scientific Officer.
Tyme’s latest patent, U.S. Patent No. 11,058,638, encompasses the Company’s pipeline of CMBTs™. To date, Tyme has developed a variety of products, including TYME-18, SM-88i, and SM-88 for various oncological applications. While TYME-18 and SM-88i are still in their preclinical phase, the Company’s SM-88 has completed various Phase I trials, with Phase II/III trials currently underway. Moreover, according to Tyme’s Q1 2021 Financial Results, the Company’s cash and cash equivalents have increased from $21.3 million as of June 30, 2021 to $26.7 million as of March 31, 2021. Looking forward, Tyme expects advancements in numerous SM-88 clinical trials, including first patient enrollment in the OASIS breast cancer trial in Q3 2021.
Tyme’s share price opened at $1.68, up from a previous close of $1.08. The Company’s shares are up 53% and are currently trading at $1.65 as of 11:04AM ET. This indicates that there has been significant change following the news.